Bicycle Therapeutics plc (BCYC)

Market Cap	964.47M
Revenue (ttm)	26.98M
Net Income (ttm)	-180.66M
Shares Out	42.43M
EPS (ttm)	-5.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137,278
Open	22.60
Previous Close	22.52
Day's Range	22.52 - 23.54
52-Week Range	12.54 - 28.91
Beta	0.89
Analysts	Strong Buy
Price Target	48.11 (+111.85%)
Earnings Date	May 10, 2024

About BCYC

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeti...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 23, 2019
• Employees: 284
• Stock Exchange: NASDAQ
• Ticker Symbol: BCYC

Financial Performance

In 2023, BCYC's revenue was $26.98 million, an increase of 86.52% compared to the previous year's $14.46 million. Losses were -$180.66 million, 60.3% more than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for BCYC stock is "Strong Buy." The 12-month stock price forecast is $48.11, which is an increase of 111.85% from the latest price.

Price Target

$48.11

(111.85% upside)

Analyst Consensus: Strong Buy